0001209191-23-059988.txt : 20231229 0001209191-23-059988.hdr.sgml : 20231229 20231229161216 ACCESSION NUMBER: 0001209191-23-059988 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231227 FILED AS OF DATE: 20231229 DATE AS OF CHANGE: 20231229 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Yednock Ted CENTRAL INDEX KEY: 0001818525 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39402 FILM NUMBER: 231527793 MAIL ADDRESS: STREET 1: C/O ANNEXON, INC. STREET 2: 180 KIMBALL WAY, SUITE 200 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Annexon, Inc. CENTRAL INDEX KEY: 0001528115 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 275414423 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1400 SIERRA POINT PARKWAY STREET 2: BLDG C, SUITE 200 CITY: BRISBANE STATE: CA ZIP: 94005 BUSINESS PHONE: (650)-822-5500 MAIL ADDRESS: STREET 1: 1400 SIERRA POINT PARKWAY STREET 2: BLDG C, SUITE 200 CITY: BRISBANE STATE: CA ZIP: 94005 4 1 doc4.xml FORM 4 SUBMISSION X0508 4 2023-12-27 0 0001528115 Annexon, Inc. ANNX 0001818525 Yednock Ted C/O ANNEXON, INC. 1400 SIERRA POINT PKWY, BLDG C, STE 200 BRISBANE CA 94005 0 1 0 0 EVP & Chief Innovation Officer 1 Common Stock 2023-12-27 4 M 0 10615 1.4096 A 10615 D Common Stock 2023-12-27 4 M 0 10385 1.8501 A 21000 D Common Stock 2023-12-27 4 S 0 21000 4.5222 D 0 D Stock Option (Right to Buy) 1.4096 2023-12-27 4 M 0 10615 0.00 D 2025-01-22 Common Stock 10615 0 D Stock Option (Right to Buy) 1.8501 2023-12-27 4 M 0 10385 0.00 D 2026-08-11 Common Stock 10385 36000 D The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted March 28, 2023. This transaction was executed in multiple trades in prices ranging from $4.50 to $4.58, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. The shares subject to the option vest are fully vested and exercisable. /s/ Jennifer Lew, as Attorney-in-Fact 2023-12-29